Fluorescence based point-of-care molecular diagnostic systems are ubiquitous in healthcare. However, many tests require that the sample be sent to a reference laboratory and read by trained medical staff which can be expensive and result in delayed analysis. Portable systems have been developed, however, detecting multiple biomarkers requires a different...

Noninvasive sampling is critical for certain patient populations, such as hemophiliacs, neonates, elderly or immunocompromised individuals, especially if they require daily monitoring. Blood sampling is painful, inconvenient and often difficult and increases the risk of exposure to infectious agents, which can be devastating to immunocompromised populations....

Ovarian cancer is one of the most common cancers among women, with over 21,000 new cases and over 14,000 deaths per year. If detected early, the 5-year survival rate is over 80%, but that drops to just 11% if detected at stage IV, and over 60% of patients are diagnosed with advanced disease. Early detection is hampered by limitations in current biomarkers,...

Despite tremendous scientific progress and treatment advances, cancer continues to be the leading cause of death worldwide, with approximately 14 million new cases and 8.2 million deaths in 2012 alone (WHO). Because invasion and metastasis are arguably the most dangerous characteristics of cancer, therapeutics that suppress these characteristics could...